Drugs / Mezigdomide
Mezigdomide
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 115 trials | ||||||
| Phase 1 | NCT07355335 | Sep 2026 → Jul 2027 expected | B-lymphoblastic leukemia/lymphoma MLL rearranged, acute myeloid leukemia with mutated NPM1 | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT07032714 | Dec 2025 → Jul 2027 expected | refractory plasma cell neoplasm | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT07105059 | Aug 2025 → Aug 2028 expected | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06048250 | Apr 2024 → Sep 2026 overdue | plasma cell myeloma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06318676 | Mar → Nov 2024 | impaired renal function disease | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06163898 | Feb 2024 → Jun 2025 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06121843 | Feb 2024 → Aug 2028 expected | plasma cell myeloma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 1 | NCT05981209 | Dec 2023 → Dec 2026 expected | plasma cell myeloma | Abdullah Khan | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05651932 | Feb 2023 → Dec 2027 expected | plasma cell myeloma | K36 Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05707390 | Feb → Sep 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05389722 | Jun → Nov 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04839809 | Jan → Oct 2021 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04560738 | Oct 2020 → May 2021 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04211545 | Oct → Dec 2019 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03803644 | Dec 2018 → May 2019 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT07612787 | Dec 2026 → Jan 2028 expected | plasma cell myeloma | University Hospital of Saint-Etienne | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07356154 | Jan 2026 → Jan 2029 expected | acute lymphoblastic leukemia, mixed phenotype acute leukemia | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06988488 | Oct 2025 → May 2027 expected | plasma cell myeloma | Celgene Corporation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06645678 | Nov 2024 → Oct 2026 expected | refractory plasma cell neoplasm | YOUNGIL KOH | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06050512 | Oct 2023 → Oct 2026 | refractory plasma cell neoplasm | Kathleen Dorritie | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05372354 | Oct 2022 → Oct 2026 expected | plasma cell myeloma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03989414 | Sep 2019 → Nov 2026 expected | plasma cell myeloma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03374085 | Feb 2018 → Aug 2025 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02343042 | Oct 2015 → Apr 2027 expected | plasma cell myeloma | Karyopharm Therapeutics Inc | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07348393 | Feb 2026 → Feb 2029 expected | refractory plasma cell neoplasm | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06627751 | May 2025 → May 2027 expected | plasma cell myeloma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT05552976 | Jan 2023 → Sep 2026 overdue | refractory plasma cell neoplasm | Bristol-Myers Squibb | Active not recruiting | Met primary |
| Phase 3 | NCT05519085 | Sep 2022 → Jan 2027 expected | refractory plasma cell neoplasm | Celgene Corporation | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06994117 Background | — | — | Bristol-Myers Squibb | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | Bristol-Myers Squibb | Regulatory U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma bms.com ↗
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM). |
| 2026-05-29 | Bristol-Myers Squibb | Results Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma bms.com ↗
Results showed MeziKd demonstrated a clinically meaningful and statistically significant improvement in progression-free survival (PFS) (95% CI: 18 months vs. 8.3 months [HR:0.48; p<0.0001]), representing a 52% reduction in the risk of disease progression or death compared with Kd. |
| 2026-03-09 | Bristol-Myers Squibb | Results Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma bms.com ↗
In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). |
| 2025-06-12 | Bristol-Myers Squibb | Results Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025 bms.com ↗
Overall response rate (ORR) was 75.0% for Cohort A and 85.2% for Cohort C, respectively. |
| 2024-11-19 | Bristol-Myers Squibb | Results Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms bms.com ↗
Results from Phase 1/2 CA057-003 trial evaluating an all-oral combination of mezigdomide and novel agents (EZH2, BET and MEK inhibitors), showing promising efficacy and no new safety signals in patients with RRMM |
| 2024-05-23 | Bristol-Myers Squibb | Results Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms bms.com ↗
New Phase 1/2 data from the targeted protein degradation platform including the novel oral CELMoD agents iberdomide in newly diagnosed multiple myeloma, mezigdomide in relapsed/refractory multiple myeloma, and golcadomide in first-line LBCL and relapsed/refractory FL, reinforcing promising activity. |
| 2023-12-11 | Bristol-Myers Squibb | Results Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs bms.com ↗
New results from the Phase 1 CC-92480-MM-002 study of oral CELMoD agent mezigdomide, including first results for cohorts evaluating mezigdomide and dexamethasone with monoclonal antibodies (anti-CD38 mAbs) daratumumab and elotuzumab |
| 2023-05-11 | Bristol-Myers Squibb | Results Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023 bms.com ↗
Results from a dose-expansion cohort of the Phase 1/2 CC-92480-MM-001 study, evaluating novel CELMoD agent, mezigdomide, with dexamethasone in patients with relapsed/refractory multiple myeloma, showed the combination’s safety profile and promising efficacy in patients with triple-class refractory multiple myeloma. |
| 2023-02-02 | Bristol-Myers Squibb | Results Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022 bms.com ↗
First results from the dose expansion cohort of the Phase 1/2 study evaluating the novel oral CELMoD agent, mezigdomide with dexamethasone (DEX), showing durable efficacy and a manageable safety profile in patients who were highly refractory to multiple prior therapies. |
| 2022-12-12 | Bristol-Myers Squibb | Results Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio bms.com ↗ |
| 2020-11-11 | Bristol-Myers Squibb | Results Bristol Myers Squibb Showcases Research Advancing Outcomes Addressing Hard-to-Treat Blood Cancers and Diseases Across Small Molecule, Biologic and Cell Therapies at ASH 2020 bms.com ↗
Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel CELMoD Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma |
All press releases naming this drug 12 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mezigdomide | “Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC-92480), a novel cereblon E3 ligase modulator.” PMID 37705327 ↗ Sep 202322“Start with 14 days of Mezigdomide. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.” NCT07105059 ↗ “Mezigdomide (also known as CC-92480 or BMS-986348) is a novel, highly potent cereblon (CRBN)-E3 ligase modulating drug (CELMoD)” NCT07348393 ↗ “A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma” NCT07612787 ↗ “mezigdomide” NCT03374085 ↗ |
| Known as | BMS-986348 | “A Phase 1, Parallel-group, 3-part, 2-period, Fixed-sequence, Crossover, Open-label, Nonrandomized, Drug-drug Interaction Study to Assess the Pharmacokinetics of CC-92480...” NCT05389722 ↗1“Mezigdomide (also known as CC-92480 or BMS-986348) is a novel, highly potent cereblon (CRBN)-E3 ligase modulating drug (CELMoD)” NCT07348393 ↗ |
| Known as | CC-92480 | “Mezigdomide (also known as CC-92480 or BMS-986348) is a novel, highly potent cereblon (CRBN)-E3 ligase modulating drug (CELMoD)” NCT07348393 ↗ |
| Known as | CPD. 3(CC-92480) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4648616 ↗ |
| Known as | MEZIGDOMIDE (CC-92480) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4648616 ↗ |
| Action | Inhibit | “Mezigdomide blocks important processes in myeloma cells” NCT06627751 ↗ |
| Modality | Small molecule | “It is an oral small-molecule compound” NCT06050512 ↗ |
| Route | Oral | “we administered oral mezigdomide in combination with dexamethasone to patients with relapsed and refractory myeloma.” PMID 37646702 ↗ Aug 2023 |